Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...

Maze seeks as much as $133 mln in New York IPO Backers include Alphabet's GV and Third Rock Ventures Biotech IPOs set for ramp up in coming weeks Jan 27 (Reuters) - Drug developer Maze ...

Treat tantrums like anxiety attacks The creator’s game-changing tip involves addressing meltdowns ... In the TikTok, she explains her go-to method: handing her child an ice cube and letting them throw ...